Author Affiliations: Minneapolis Veterans Affairs Medical Center and University of Minnesota, Minneapolis.
accounts for approximately 500,000 cases of pneumonia,
50,000 cases of bacteremia, and 40,000 deaths each
year.1 Vaccination of adults with the pneumococcal
polysaccharide vaccine has not been convincingly demonstrated to reduce
the risk for pneumonia among groups currently targeted for
vaccination2 but is associated with substantial reductions
in invasive disease.1 Among the elderly, vaccination is not
only cost-effective but cost saving for the prevention of
bacteremia.3 Few other diagnostic or therapeutic
interventions can make such a claim.
Nichol KL. Revaccination of High-Risk Adults With Pneumococcal Polysaccharide Vaccine. JAMA. 1999;281(3):280-281. doi:10.1001/jama.281.3.280